The Journal of pharmacology and experimental therapeuticsAnimalsRivaroxabanRatsMaleInflammation
Mitigation of thromboinflammation by rivaroxaban ameliorates metabolic and structural manifestations of metabolic dysfunction-associated steatohepatitis in rats: Comparison to other antithrombotic drugs.
Basant Rageh, Marium Shamaa, Mahmoud Agami, Ahmed F El-Yazbi, Ahmed Wahid
Published: 202510.1016/j.jpet.2025.103749
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) poses a significant public health challenge, characterized by liver fat accumulation accompanied with inflammation and cell damage. Patients with MASH commonly exhibit hypercoagulability. Our pr…
Preview only. Read the full abstract at the source